BioAlliance Pharma announces that Therabel launches Loramyc®

in Germany with the support of Hikma

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that Loramyc® has been launched in Germany by its European partner Therabel. Therabel has created a fully dedicated team and has also entered into a co-promotion agreement with Hikma Pharma GmbH, a leading specialty pharmaceutical group focused on branded and generic products in Oncology.
“These significant efforts mark a positive and concrete step forward of our European partnership with Therabel”, stated Dominique Costantini, CEO of BioAlliance Pharma. “We are very confident in Therabel and Hikma teams’ involvement and know-how to ensure Loramyc® success in Germany”.
“Our team is committed to create an hospital presence through Loramyc® with oncologists and HIV specialists and we are delighted to deepen this presence further with the experience and support of the Hikma sales force directed to private oncologists and haematologists”, said Jean-Michel Robert, President of Therabel Strategic Committee.
Loramyc® is a mucoadhesive gingival tablet containing miconazole administered once-a-day over 7 to 14 days and is indicated for the treatment of oropharyngeal candidiasis in immune compromised patients.

110516_EN_Loramyc Germany Launch